title: Dopamine D1-like and D2-like receptors in the dorsal striatum control different aspects of attentional performance in the five-choice serial reaction time task under a condition of increased activity of corticostriatal inputs.
abstract: We investigated the interaction between the corticostriatal glutamatergic afferents and dopamine D1-like and D2-like receptors in the dorsomedial striatum (dm-STR) in attention and executive response control in the five-choice serial reaction time (5-CSRT) task. The competitive NMDA receptor antagonist 3-(R)-2-carboxypiperazin-4-propyl-1-phosphonic acid (CPP) injected in the mPFC impaired accuracy and increased premature and perseverative responding, raising GLU, DA, and GABA release in the dm-STR. The D1-like antagonist SCH23390 injected in the dm-STR reversed the CPP-induced accuracy deficit but did not affect the increase in perseverative responding. In contrast, the D2-like antagonist haloperidol injected in the dm-STR reduced the CPP-induced increase in perseverative responding but not the accuracy deficit. The different roles of dorsal striatal D1-like and D2-like receptor were further supported by the finding that activation of D1-like receptor in the dm-STR by SKF38393 impaired accuracy but not perseverative responding while the D2-like agonist quinpirole injected in the dm-STR increased perseverative responding but did not affect accuracy. These findings suggest that integration of cortical information by D1-like receptors in the dm-STR is a key mechanism of the input selection process of attention while the integration of corticostriatal signals by D2-like receptors preserves the ability to switch from one act/response to the next in a complex motor sequence, thus providing for behavioral flexibility.
authors.affiliation: Department of Neuroscience, Laboratory of Neurochemistry and Behavior, Istituto di Ricerche Farmacologiche 'Mario Negri', via G. La Masa 19, Milano, Italy.
authors.forename: Laura
authors.initials: L
authors.lastname: Agnoli
authors.forename: Pierangela
authors.initials: P
authors.lastname: Mainolfi
authors.forename: Roberto W
authors.initials: RW
authors.lastname: Invernizzi
authors.forename: Mirjana
authors.initials: M
authors.lastname: Carli
mesh_terms: D000596:Amino Acids / Q000378:metabolism; D000704:Analysis of Variance; D000818:Animals; D001288:Attention / Q000187:drug effects / Q000502:physiology*; D001289:Attention Deficit Disorder with Hyperactivity / Q000139:chemically induced / Q000188:drug therapy; D002755:Choice Behavior / Q000187:drug effects / Q000502:physiology*; D002851:Chromatography, High Pressure Liquid; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism*; D015259:Dopamine Agents / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D018691:Excitatory Amino Acid Antagonists / Q000009:adverse effects; D008297:Male; D017551:Microdialysis; D010879:Piperazines / Q000009:adverse effects; D017397:Prefrontal Cortex / Q000187:drug effects / Q000502:physiology; D051381:Rats; D011930:Reaction Time / Q000187:drug effects / Q000502:physiology*; D017447:Receptors, Dopamine D1 / Q000378:metabolism*; D017448:Receptors, Dopamine D2 / Q000378:metabolism*
chemical_list: D000596:Amino Acids; D015259:Dopamine Agents; D018691:Excitatory Amino Acid Antagonists; D010879:Piperazines; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; C050592:3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid